242 related articles for article (PubMed ID: 26400962)
1. ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
Hathcock KS; Padilla-Nash HM; Camps J; Shin DM; Triner D; Shaffer AL; Maul RW; Steinberg SM; Gearhart PJ; Staudt LM; Morse HC; Ried T; Hodes RJ
Blood; 2015 Nov; 126(20):2291-301. PubMed ID: 26400962
[TBL] [Abstract][Full Text] [Related]
2. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
3. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
5. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
Kim SH; Cheong JW; Park KH; Kim TS; Yang WI
Arch Pathol Lab Med; 2007 Mar; 131(3):457-67. PubMed ID: 17516749
[TBL] [Abstract][Full Text] [Related]
7. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.
Vicente-Dueñas C; Fontán L; Gonzalez-Herrero I; Romero-Camarero I; Segura V; Aznar MA; Alonso-Escudero E; Campos-Sanchez E; Ruiz-Roca L; Barajas-Diego M; Sagardoy A; Martinez-Ferrandis JI; Abollo-Jimenez F; Bertolo C; Peñuelas I; Garcia-Criado FJ; García-Cenador MB; Tousseyn T; Agirre X; Prosper F; Garcia-Bragado F; McPhail ED; Lossos IS; Du MQ; Flores T; Hernandez-Rivas JM; Gonzalez M; Salar A; Bellosillo B; Conde E; Siebert R; Sagaert X; Cobaleda C; Sanchez-Garcia I; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10534-9. PubMed ID: 22689981
[TBL] [Abstract][Full Text] [Related]
8. Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
Wimberger N; Ober F; Avar G; Grau M; Xu W; Lenz G; Menden MP; Krappmann D
Blood; 2023 Dec; 142(23):1985-2001. PubMed ID: 37623434
[TBL] [Abstract][Full Text] [Related]
9. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
[TBL] [Abstract][Full Text] [Related]
10. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
11. Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.
Wu CH; Yang YH; Chen MR; Tsai CH; Cheng AL; Doong SL
PLoS One; 2018; 13(6):e0199779. PubMed ID: 29953499
[TBL] [Abstract][Full Text] [Related]
12. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
[TBL] [Abstract][Full Text] [Related]
13. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
[TBL] [Abstract][Full Text] [Related]
14. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
15. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
[TBL] [Abstract][Full Text] [Related]
16. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
18. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
19. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
